NCT05410015

Brief Summary

The relationship between immune inflammation-related protein complexes inblood and recurrence or metastasis of ovarian cancer will be studied

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
300

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Feb 2022

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 3, 2022

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

June 4, 2022

Completed
4 days until next milestone

First Posted

Study publicly available on registry

June 8, 2022

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 3, 2024

Completed
2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

February 3, 2026

Completed
Last Updated

June 8, 2022

Status Verified

March 1, 2022

Enrollment Period

2 years

First QC Date

June 4, 2022

Last Update Submit

June 4, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • Immune Inflammation-Related Protein Pomplexes

    The change of immune inflammation-related protein complexes

    2 years

Interventions

Normal clinical treatment without intervention

Eligibility Criteria

Age20 Years - 70 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

The study population included normal ovarian controls, patients with benign ovarian disease, and patients with malignant epithelial ovarian cancer.

You may qualify if:

  • Female
  • Normal ovary control
  • Ovarian benign disease
  • Ovarian malignant epithelial carcinoma

You may not qualify if:

  • Male
  • Age above 70
  • Suffering from other malignant tumors
  • Non-compliant patient

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Peking Union Medical College Hospital

Beijing, Beijing Municipality, China

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

1 mL of serum

MeSH Terms

Conditions

Ovarian Neoplasms

Interventions

Methods

Condition Hierarchy (Ancestors)

Endocrine Gland NeoplasmsNeoplasms by SiteNeoplasmsOvarian DiseasesAdnexal DiseasesGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital Neoplasms, FemaleUrogenital NeoplasmsGenital DiseasesEndocrine System DiseasesGonadal Disorders

Intervention Hierarchy (Ancestors)

Investigative Techniques

Central Study Contacts

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 4, 2022

First Posted

June 8, 2022

Study Start

February 3, 2022

Primary Completion

February 3, 2024

Study Completion

February 3, 2026

Last Updated

June 8, 2022

Record last verified: 2022-03

Data Sharing

IPD Sharing
Will not share

Locations